Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Moves To Boost Use Of Alternatives To Animal Testing

Executive Summary

Alternative approaches to animal models, such as improved tests based on human and animal cells, provide opportunities to develop better and more predictive scientific tools, the European Medicines Agency says.

You may also be interested in...



AdvaMed Launches Ethics Code To Meet ‘Business And Market Realities’ In India

Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.

EMA Tells Marketing Authorization Applicants How To Run Registry-Based Studies

Advice on the acceptability of registry-based studies as a source of evidence for regulatory purposes is included in new guidance from the European Medicines Agency.

Blow For Seagen As England Rejects Funding For Advanced Breast Cancer Drug Tukysa

England’s health technology assessment body said it would continue to work with Seagen to address the reasons why its newly published draft guidance has recommended against using Tukysa on the National Health Service.

Topics

UsernamePublicRestriction

Register

PS145029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel